zifeng-ai/TrialReviewBench huggingface dataset:
Clinical trial study (PMID 29812997)
Country: Western
Sample size: 26
Median age (range): 18-70
Sex (male/female): 13/13
Lines of prior treatment: 10 (3-19)
Autologous stem cell transplantation before CAR-T: 85%
Lymphodepletion: Fludarabine/Cyclophosphamide: 30mg/m2/300mg/m2 daily on day -5 to -3
Antigen: B cell maturation antigen
CAR construct (vector/costimulatory molecule/scFv species): γ-retrovirus/CD28/murine
T cell origin: Autologous
T cell subset: CD4/CD8
BCMA positivity requirement at enrollment: >50%
CAR-T dose: 0.3-9.0x106/Kg
Follow-up: Median 20 weeks
Clinical trial study (PMID 30572922)
Country: Eastern
Sample size: 57
Median age (range): 54 (27-72)
Sex (male/female): 34/23
Lines of prior treatment: 3 (1-9)
Autologous stem cell transplantation before CAR-T: 18%
Lymphodepletion: Cyclophosphamide:300 mg/m2 on day -5 to -3
Antigen: B cell maturation antigen
CAR construct (vector/costimulatory molecule/scFv species): Lentivirus/4-1BB/Llama
T cell origin: Autologous
T cell subset: Unselected
BCMA positivity requirement at enrollment: Required (cutoff not reported)
CAR-T dose: Median 0.5 (0.07-2.1)x106/Kg
Follow-up: Median 32 (2.8-82.8) weeks
Clinical trial study (PMID 31042825)
Country: Western
Sample size: 33
Median age (range): 60 (37-75)
Sex (male/female): 21/12
Lines of prior treatment: 7 (3-23)
Autologous stem cell transplantation before CAR-T: 97%
Lymphodepletion: Fludarabine/Cyclophosphamide: 30mg/m2/300mg/m2 daily on day -5 to -3
Antigen: B cell maturation antigen
CAR construct (vector/costimulatory molecule/scFv species): Lentivirus/4-1BB/murine
T cell origin: Autologous
T cell subset: CD4/CD8
BCMA positivity requirement at enrollment: Dose-escalation: ≥50%; dose-expansion: not reported
CAR-T dose: 50-800x106
Follow-up: Median 45 (24.8-91.2) weeks
Clinical trial study (PMID 30988175)
Country: Eastern
Sample size: 17
Median age (range): 55 (35-73)
Sex (male/female): 11/6
Lines of prior treatment: 5 (3-11)
Autologous stem cell transplantation before CAR-T: 47%
Lymphodepletion: Fludarabine/Cyclophosphamide: 25 mg/m2 daily for 3 days/250/300mg/m2
Antigen: B cell maturation antigen
CAR construct (vector/costimulatory molecule/scFv species): Lentivirus/4-1BB/Llama
T cell subset: CD4/CD8
BCMA positivity requirement at enrollment: Required (cutoff not reported)
CAR-T dose: 0.21-1.52x106/Kg
Follow-up: Median 60 (1.7-76.4) weeks
Clinical trial study (PMID 30896447)
Country: Western
Sample size: 25
Median age (range): 58 (44-75)
Sex (male/female): 17/8
Lines of prior treatment: 7 (3-13)
Autologous stem cell transplantation before CAR-T: 92%
Lymphodepletion: Cyclophosphamide: 1.5g/m2 or no Lymphodepletionmphodepletion
Antigen: B cell maturation antigen
CAR construct (vector/costimulatory molecule/scFv species): Lentivirus/4-1BB/human
T cell origin: Autologous
T cell subset: CD4/CD8
BCMA positivity requirement at enrollment: Not required
CAR-T dose: 1-50x107
Follow-up: Median 54 weeks
Clinical trial study (PMID 30830874)
Country: Western
Sample size: 10
Median age (range): 61 (48-68)
Sex (male/female): 4/6
Lines of prior treatment: 6 (2-10)
Autologous stem cell transplantation before CAR-T: 100%
Lymphodepletion: Melphalan: 140-200 mg/m2
Antigen: CD19
CAR construct (vector/costimulatory molecule/scFv species): Lentiviral/4-1BB
T cell origin: Autologous
T cell subset: Unselected
BCMA positivity requirement at enrollment: not reported
CAR-T dose: 1-5x107
Follow-up: >14 weeks
Clinical trial study (PMID 27270177)
Country: Western
Sample size: 8
Median age (range): 56.5 (43-69)
Sex (male/female): 3/5
Antigen: κ light chain
CAR construct (vector/costimulatory molecule/scFv species): Retroviral/CD28/murine
T cell origin: Autologous
T cell subset: CD4/CD8
BCMA positivity requirement at enrollment: not reported
CAR-T dose: 0.2-2x108/m2
Follow-up: (6-96) weeks
Clinical trial study (PMID 30396908)
Country: Western
Sample size: 5
Median age (range): 70 (44-79)
Sex (male/female): 3/2
Lines of prior treatment: ≥5
Autologous stem cell transplantation before CAR-T: 100%
Lymphodepletion: No Lymphodepletion
Antigen: NKG2D-ligands
CAR construct (vector/costimulatory molecule/scFv species): γ-retroviral/NKG2D-CAR
T cell origin: Autologous
T cell subset: CD4/CD8
BCMA positivity requirement at enrollment: not reported
CAR-T dose: 1x106-3×107
Follow-up: (14-107) weeks
Clinical trial study (PMID 31378662)
Country: Eastern
Sample size: 21
Median age (range): 58 (49.5-61)
Sex (male/female): not available
Lines of prior treatment: 6 (5-8)
Autologous stem cell transplantation before CAR-T: 14%
Lymphodepletion: Fludarabine/Cyclophosphamide: 30mg/m2 for 3 days /750mg/m2 daily for 1 day
Antigen: CD19 and B cell maturation antigen
CAR construct (vector/costimulatory molecule/scFv species): Lentiviral/4-1BB/human (anti-CD19) murine (anti-B cell maturation antigen)
T cell origin: Autologous
T cell subset: Unselected
BCMA positivity requirement at enrollment: not reported
CAR-T dose: CD19(1×10^6/Kg) B cell maturation antigen (1×10^6/Kg)
Follow-up: Median 25.6 (10.3-42.1) weeks